Bispecific Antibodies: Bridging Targets and Effector Molecules

Common LightChain Platform

Why is the Bispecific antibody important

Bispecific antibody (BsAb) is engineered to bind simultaneously to two antigens or epitopes in the same molecule. Due to this multifunctionality, it has gradually become the focus of antibody drug development. BsAb can activate immune cells by connecting them to tumor cells via molecular bridging; it can also block the interaction between the two antigens and their corresponding ligands, leading to the inhibition of the antigen-mediated signaling pathways which were related to tumor cell proliferation,diferentiation and metastasis; it can also bridge of the two molecules on the cell surface and in the extracelluar matrix to activate theirs downstream pathway in the treatment of the diabetes andhaemophilia. Moreover, through the piggybacking mechanism, BsAb can translocate to the target in the inaccessible compartment beyond the cell organelle and tissue barrier.

==Why the Common Light Chain is the Best Format of BsAB ==

As of 2024, twelve bispecific antibodies (BsAbs) have achieved regulatory approval and market entry. The majority of these therapeutics maintain natural antibody architecture, conferring several pharmacological advantages:

  • Extended serum half-life through preserved Fc region functionality
  • Optimal spatial arrangement between Fab domains
  • Appropriate molecular weight for favorable pharmacokinetics

These structural features collectively suggest an enhanced probability of clinical success for this emerging drug class.

Among these approved BsAbs, Emicizumab is a common light-chain bispecific antibody, while Amivantamab and Teclistamab are based on Genentech’s duobody technology. Mosunetuzumab and Faricimab employ Genentech’s Crossmab technology. While Genmab’s duobody technology requires the development of two antibodies and their in vitro assembly, Crossmab technology is still under patent,and its development process is complex.

Common light chain technology undoubtedly has several distinct advantages over other platforms.

  • Elimination of light chain mispairing
  • Enhanced production yields
  • Streamlined manufacturing (CMC) processes
  • Modular “plug-and-play” platform for diferent BsAb generations

The advantage of Kyinno’s Commonly Light Chain Mouse
There are two methods to generate the common light chain BsAb: phage display, which is time-consuming and has a low success rate, and transgenic mouse using a fixed light chain germline. Kyinno has successfully developed the Common Light Chain (KY-CLCTM) Mouse technology platform. The KY-CLC-mouse features no lambda (λ) light chain expression and entirely identical mouse kappa (κ) light chain (protected by patent), ofering excellent solubility and stability. The KY-CLC-mouse maintains the  diversity of the heavy chain germline and intact afinity maturation capacity, enabling rapid and eficient screening for high-afinity, highly-specific antibodies against all validated targets. Bispecific antibodies  assembled using this platform are comparable to monoclonal antibodies in expression and purification stability.

Case Studies
Leveraging our extensive expertise inantibody development and building upon the established CLC mouse model, our company ofers our valued customers rapid and eficient bispecific antibody development services. Our one-stop service platform covers a comprehensive range of activities,including antibody sequence screening, assembly, and expression of bispecific antibodies, culminating in rigorous antibody quality control analysis.

 

 

Development of anti-MET/EGFR Common light chain Bispecific Antibody

Physical and chemical parameters of the EGFRxMET CLC BsAb

 

Preliminary Stability analysis of the EGFRxMET CLC BsAb

EGFRxMET CLC BsAb displayed a stronger inhibitory efect on tumor growth.

All Antibody Discovery Services

Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heighten specificity, expand treatment options, and pave the way for future medical advancements.

Using antibodies with high specificity, Membrane Protein Antibody Discovery MPS AB5000 guarantee precise binding targets for CAR-T cells and biologics. This platform is foundational to therapeutic success and patient outcomes. Promoting next-generation healthcare solutions.

ai drug discovery service

AI Drug Discovery leverages advanced algorithms to revolutionize therapeutic antibody development by streamlining the traditionally cumbersome process.  Our AI-driven neural networks identify precise relationships between antibody and antigen structures, enabling the virtual generation of innovative antibody drugs.